Report: Building successful cell and gene therapy supply chains
By AmerisourceBergen
This report from Scrip Pharma Intelligence summarizes the takeaways from a recent roundtable with a panel of experts representing early stage biotech, pharmaceutical, supply chain management and logistics companies:
- Orchestrating cell and gene therapies requires bespoke solutions in terms of storage, transportation, timelines, temperature control, and servicer flexibility
- In these incredibly complex supply chains, forming and orchestrating partnerships is a necessity
- In order for logistics vendors to form partnerships with cell and gene therapy manufacturers it is important to understand each company's unique requirements
- Scalability of logistics solutions is also an important consideration
![](/-/media/assets/worldcourier/english/images/content-thumbnails/scrip-informa-logo.png)
Topics:
Cell and gene therapy